These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [We must learn how to be better to evaluate drug benefits and risks]. Dahl E Lakartidningen; 2005 Jun 27-Jul 10; 102(26-27):2003-4. PubMed ID: 16044759 [No Abstract] [Full Text] [Related]
23. Secrecy and the health protection branch. Lexchin J CMAJ; 1998 Sep; 159(5):481-3. PubMed ID: 9757171 [No Abstract] [Full Text] [Related]
24. [We don't receive sufficient information about calcium blockers and other drugs]. Lindeberg S Lakartidningen; 1995 Oct; 92(43):3977. PubMed ID: 7475518 [No Abstract] [Full Text] [Related]
26. User applications of health economics data. Navarro RP Med Interface; 1996 Mar; 9(3):81-2. PubMed ID: 10156017 [No Abstract] [Full Text] [Related]
27. [Marketing of inhalation steroids is more confusing than informative]. Arnesen O Tidsskr Nor Laegeforen; 1994 Nov; 114(28):3360. PubMed ID: 7809900 [No Abstract] [Full Text] [Related]
28. [Physicians notify on drug industry's marketing]. Perman E Lakartidningen; 2004 Mar; 101(11):1014-5. PubMed ID: 15055124 [No Abstract] [Full Text] [Related]
29. [User guidelines on drug packages--written for whom, approved by whom?]. Ugeskr Laeger; 1996 Apr; 158(17):2404-5. PubMed ID: 8686000 [No Abstract] [Full Text] [Related]
30. [One year's written drug information to a general practitioner]. Molaug PO; Spigset O Tidsskr Nor Laegeforen; 2001 Feb; 121(5):585-8. PubMed ID: 11301615 [TBL] [Abstract][Full Text] [Related]
31. [Written drug advertisements]. Kormeset PO Tidsskr Nor Laegeforen; 2006 Aug; 126(15):1946; author reply 1946-7. PubMed ID: 16915329 [No Abstract] [Full Text] [Related]
32. Direct-to-consumer advertising of prescription drugs: balancing benefits and risks, and a way forward. Kravitz RL; Bell RA Clin Pharmacol Ther; 2007 Oct; 82(4):360-2. PubMed ID: 17851573 [No Abstract] [Full Text] [Related]
33. A consumer-empowered response to direct-to-consumer advertising of prescription drugs. Kemper DW; Mettler M Manag Care Q; 2002; 10(2):52-4. PubMed ID: 12148483 [TBL] [Abstract][Full Text] [Related]
34. [Physicians report verbal drug information. Cases scrutinized by the IGM]. Perman E Lakartidningen; 2004 Aug; 101(35):2648, 2650. PubMed ID: 15458219 [No Abstract] [Full Text] [Related]
35. Drug policy: the challenge is to overcome fragmentation. McFarlance A Healthc Pap; 2002; 3(1):38-42: discussion 87-94. PubMed ID: 12811109 [TBL] [Abstract][Full Text] [Related]
36. Drug detailing in the hospital: background for policy development. Chan J; Einarson T Can J Hosp Pharm; 1991 Jun; 44(3):161-6. PubMed ID: 10112744 [No Abstract] [Full Text] [Related]
37. [Worry about the IGM is not justified]. Mandahl H Lakartidningen; 1997 Jul; 94(28-29):2529. PubMed ID: 9254309 [No Abstract] [Full Text] [Related]
38. Drug information residency rotation with pharmaceutical industry. Cramer RL Am J Pharm Educ; 1986; 50(2):154-6. PubMed ID: 10277398 [TBL] [Abstract][Full Text] [Related]
39. Using information services to gain a competitive advantage. Malloy S Biotechnology (N Y); 1994 Dec; 12(13):1381-4. PubMed ID: 7765571 [No Abstract] [Full Text] [Related]
40. Timeliness of receipt of manufacturers' new product information. Murdoch LA; Lum L Can J Hosp Pharm; 1991 Oct; 44(5):235-8. PubMed ID: 10115576 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]